The Immunogenicity of Hemophilus influenzae Type B Polysaccharide--Neisseria meningitidis Group B Outer Membrane Protein Complex Vaccine in Infants and Young Children

Publisher Website
Google Scholar
Abstract
Hemophilus influenzae type b polysaccharide—Neisseria meningitidis group Bouter membrane protein complex vaccine wasadministered in a single dose to 38 children ages 24–53 mo (group 1)and to 78 children ages 12–23 mo (group 2) and in two doses to 84 children ages 2–11 mo (group 3). The geometric mean concentration of the capsular antibody before and after the vaccine regimen, respectively, were 0.35 µg/ml and 12.59 µg/ml in group 1, 0.18 µg/ml and 4.79 µg/ml in group 2, and 0.15 µg/ml and 3.80 µg/ml in group 3. After completing the vaccine regimen, concentrations of capsular antibody were ≥0.15 µg/ml in 199 (99.5%) of the 200 children and ≥1.0 µg/ml in 168 (84%) of the children. There were no serious and few minor adverse reactions to the vaccine. This vaccine is immunogenic in infants and young children.